NYSE:PFE - Pfizer Stock Price, Forecast & News

Pfizer's stock was trading at $32.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PFE shares have decreased by 3.9% and is now trading at $30.90. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Pfizer.

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Pfizer.

Pfizer Inc. (NYSE:PFE) posted its earnings results on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 EPS for the quarter, missing analysts' consensus estimates of $0.57 by $0.02. The biopharmaceutical company earned $12.69 billion during the quarter, compared to analyst estimates of $12.73 billion. Pfizer had a return on equity of 27.01% and a net margin of 31.44%. The business's revenue was down 9.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 earnings per share. View Pfizer's earnings history.

Pfizer announced a quarterly dividend on Monday, December 16th. Stockholders of record on Friday, January 31st will be paid a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 annualized dividend and a dividend yield of 4.92%. The ex-dividend date is Thursday, January 30th. This is a positive change from Pfizer's previous quarterly dividend of $0.36. View Pfizer's dividend history.

Pfizer announced that its Board of Directors has initiated a stock repurchase plan on Friday, December 14th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's management believes its shares are undervalued.

Pfizer updated its FY20 earnings guidance on Tuesday, January, 28th. The company provided earnings per share (EPS) guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.

12 equities research analysts have issued 12-month target prices for Pfizer's stock. Their forecasts range from $36.00 to $53.00. On average, they anticipate Pfizer's stock price to reach $41.48 in the next year. This suggests a possible upside of 34.2% from the stock's current price. View analysts' price targets for Pfizer.

News coverage about PFE stock has been trending positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pfizer earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutPfizer.

Pfizer saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 59,077,400 shares, an increase of 10.1% from the February 27th total of 53,670,000 shares. Based on an average daily volume of 25,250,000 shares, the short-interest ratio is presently 2.3 days. Currently, 1.1% of the company's stock are sold short. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Verizon Communications (VZ), Johnson & Johnson (JNJ), Intel (INTC), General Electric (GE), Bank of America (BAC), AbbVie (ABBV), Walt Disney (DIS) and Exxon Mobil (XOM).

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (5.27%), Capital World Investors (3.41%), Geode Capital Management LLC (1.61%), Bank of New York Mellon Corp (1.08%), Norges Bank (1.07%) and Massachusetts Financial Services Co. MA (0.94%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View institutional ownership trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Massachusetts Financial Services Co. MA, PGGM Investments, California Public Employees Retirement System, LSV Asset Management, CI Investments Inc., PNC Financial Services Group Inc., and KBC Group NV. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, and Frank A Damelio. View insider buying and selling activity for Pfizer.

PFE stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Capital World Investors, Renaissance Technologies LLC, Marshall Wace North America L.P., Macquarie Group Ltd., Sanders Capital LLC, Bank of New York Mellon Corp, and FIL Ltd. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, and Scott Gottlieb. View insider buying and selling activity for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $30.90.

Pfizer has a market capitalization of $171.42 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe. View additional information about Pfizer.

The official website for Pfizer is http://www.pfizer.com/.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.